AnaptysBio Announces Appointment of Hollings Renton and John Schmid to Board of Directors
Adds Strategic Planning and Corporate Finance Expertise to Board
SAN DIEGO, June 30, 2015 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the appointment of Hollings Renton and John Schmid to its Board of Directors.
"We are pleased to welcome Hollings and John to AnaptysBio's Board of Directors," said Hamza Suria, President & CEO of AnaptysBio. "They each bring a strong track record of Board leadership, strategic planning and corporate finance in the biotech sector. We look forward to working with Hollings and John in advancing AnaptysBio's strategic vision to build a robust pipeline of therapeutic antibodies focused on emerging opportunities in inflammation and immuno-oncology, led by our first-in-class anti-IL-33 and anti-IL-36 receptor antibody programs."
Mr. Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008. From 1991 to 1993, Mr. Renton served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. He served as President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton serves as chairman of the board of Portola Pharmaceuticals, Inc., and is a member of the board of Cepheid, Inc. and Kythera Biopharmaceuticals, Inc. He previously served on the boards of directors of Rigel Pharmaceuticals, Inc., Affymax, Inc., Sangstat Medical Corporation, Special Olympics Northern California and the Biotechnology Industry Organization. Mr. Renton received a B.S. in Mathematics from Colorado State University and a M.B.A. from the University of Michigan.
Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. He currently serves as a director of Neos Therapeutics, Inc. and chairman of the board of directors of Speak, Inc. Mr. Schmid holds a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.
About AnaptysBio
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company's first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO. For more information, visit www.anaptysbio.com.
Contacts:
Julie Rathbun
[email protected]
206-769-9219
Logo - http://photos.prnewswire.com/prnh/20111205/SF16052LOGO
SOURCE AnaptysBio
Share this article